Persona.
Do we buy the category —
or just enter it?
A fully-executed LOI is on the table to acquire Persona, a personalized-supplement platform. This is the honest case for what it's worth, what it isn't, and how to move without betting the company on it.
Two decisions wearing one LOI.
Almost every argument for and against gets clearer once you separate them:
- Decision A — the category. Should OrderlyMeds sell supplements (prepackaged & personalized), DTC and B2B, at all? Mostly a strategy question.
- Decision B — the vehicle. Is acquiring Persona, now, at full scale the right way in? A capital & timing question.
You can be a hard yes on A and a not-yet on B without contradiction. This deck answers your ten questions in that order and lands on a structure that lets both be true.
The lens for the whole deck
By slide 10 we're testing your own hypothesis: is the hesitation about Persona a…
- Cash availability problem? → change the terms
- Dead category problem? → walk away
- Distraction / timing problem? → push & lock in
Should we sell supplements to the people we already have?
Our GLP-1 patients are already buying nutrition — protein, fiber, electrolytes — just not from us. ~30% buy protein on their own. The peers who make nutrition work (Ivim at $125/mo, Shed free with first script) sell a stack, not a science project.
So the prepackaged, GLP-1-companion stack is a clear yes: it's demand we already created and hand to someone else.
The "personalized" caveat
Personalization sold as a 5-minute questionnaire is a thin differentiator with no clinical moat — it's exactly what failed at Care/of. Personalization becomes real only when it's driven by biomarkers (our blood-testing play), not a quiz.
- Lead with the stock stack now
- Earn "personalized" by attaching bloodwork
Do we bolt supplements onto HealthGrid for the medspas & telehealths on our rails?
This is the "arms-dealer" model. Hims, Ro, and Noom all sell products built by someone else — the brand is the product, the infrastructure is invisible.
HealthGrid already gives medspas and telehealths our telehealth + fulfillment experience. A supplement capability plugged into that grid means we monetize their patient relationships without paying to acquire a single one.
- We already have the rails. Intake, prescriber network, fulfillment, compliance.
- Attach, don't acquire. Their patients, our margin.
- Stickier partners. A partner who fulfills supplements through us is far harder to churn.
- Same engine, two revenue lines. DTC (OrderlyMeds) + B2B (HealthGrid) off one supply chain.
Will medspas actually take a private-label line?
What medspas want
Margin on the shelf, their own brand on the bottle, and zero operational lift. Supplements are already a high-margin retail line for them.
Where it works
Turnkey private-label stock stacks they can put their logo on and reorder in one click. That's a proven medspa behavior.
Where it's fragile
Personalization adds intake friction and SKU complexity most medspas won't operate. Offer it as a premium tier, not the default.
Net: sell them the easy thing first — private-label stock stacks fulfilled by us — and let personalization be the upsell that our bloodwork + telehealth make effortless. Don't lead with the part they won't run.
Is this real diversification — or a rounding error?
Our revenue is concentrated in compounded GLP-1 — a line exposed to regulatory and pricing cliffs. Supplement revenue is uncorrelated to that risk.
Persona's own model shows the shape: it's a fixed-cost base today, but every +$200K/mo of revenue drops to a high six-figure annual profit, and +$1M/mo makes it "very profitable" with no material capex — because free inventory turns into cash fast.
Targeting ~10% of revenue diversity is a meaningful hedge, not a moonshot — and it compounds with retention (slide 06).
Does owning the supply chain build enterprise value?
The comps we admire — Hims (MedisourceRx, Trybe), Ro (Kit, Workpath), Noom (Tailor Made) — bought real manufacturing after the model proved out. That's what re-rates a company from reseller to vertically-integrated platform.
Persona isn't that. It's a packaging & personalization operation: the formulary is developed with a contract manufacturer that makes the actual product; Persona buys it and packs it to the individual. So the "owned supply chain" we'd acquire is pack-out + formulations + brand — not the upstream manufacturing margin.
So where's the enterprise value?
Not machine-level cost capture. The durable value is owning the formulary IP, the personalization engine, the brand and the customer book — plus the option to bring manufacturing in-house later, once volume justifies it.
- Product is still made by a contract manufacturer — the CM keeps that margin
- Equipment is largely packaging automation, not a plant
- WA health-data law limits marketing use of assessment data — counsel early
Does this keep customers longer? Yes — and that's the whole game.
- Supplements + quarterly bloodwork make patients sticky. Someone watching their A1c drop doesn't cancel. (SiPhox: ~3× more likely to stay on program with real bloodwork behind it.)
- They catch the churn we lose today. When a patient comes off GLP-1, a supplement + testing plan retains them instead of losing them entirely.
- B2B lock-in. A HealthGrid partner whose supplement line runs through us has real switching costs.
Why retention beats revenue here
The direct margin on a supplement stack is nice. The durability it adds to refill revenue is the actual value — it makes every dollar of our core book worth more, on both sides of the business.
Priority: supplements vs. the rest of the roadmap.
| Initiative | Revenue | Strategic / EV | Retention | Speed / low effort | Capital light | Seq. |
|---|---|---|---|---|---|---|
| Core GLP-1 · peptides · hormones · generics | ${bar(5)} | ${bar(5)} | ${bar(4)} | ${bar(4)} | ${bar(4)} | 0 · engine |
| B2B sales · HealthGrid | ${bar(4)} | ${bar(5)} | ${bar(4)} | ${bar(3)} | ${bar(4)} | 1 |
| Diagnostic blood (partner) | ${bar(3)} | ${bar(4)} | ${bar(5)} | ${bar(5)} | ${bar(5)} | 1 |
| Supplements — enter (partner) | ${bar(3)} | ${bar(4)} | ${bar(5)} | ${bar(4)} | ${bar(4)} | 2 |
| Health-tech integration | ${bar(2)} | ${bar(4)} | ${bar(3)} | ${bar(3)} | ${bar(3)} | 2 |
| Supplements — own (Persona) | ${bar(4)} | ${bar(5)} | ${bar(4)} | ${bar(2)} | ${bar(1)} | 3 · gated |
| HealthBrain | ${bar(2)} | ${bar(5)} | ${bar(3)} | ${bar(2)} | ${bar(3)} | 3 |
| Build MSO | ${bar(4)} | ${bar(4)} | ${bar(2)} | ${bar(1)} | ${bar(1)} | 4 |
The read: entering supplements (partner) sits high — cheap, fast, retention-rich — and pairs naturally with blood diagnostics, which is what makes personalization real. Owning supplements (Persona) is strategically top-tier but capital-heavy and slow, so it's gated behind proof, not a day-one bet ahead of the core engine.
How we get the capability: the trade-off, cell by cell.
BuyAcquire Persona |
BuildOwn line from scratch |
PartnerVitalabs / Fullscript / Makers dropship |
|
|---|---|---|---|
| Tech build intake funnel · checkout · fulfillment |
InheritedAssessment funnel, checkout & fulfillment tech + facility come with the deal. | We buildWe own the telehealth stack already, but supplement intake/fulfillment is net-new eng. | MinimalDropship under our brand; partner's fulfillment. Light lift on our site. |
| Cost of goods owned vs. fulfilled by others |
Owns pack-outOwns packaging + formulary, but the active product is still bought from a contract manufacturer — a real COGS edge, narrower than "owned manufacturing." | 2nd — owned, laterOwned eventually, but slow to reach scale & unit cost. | Worst — partner cutPartner takes the margin; thinnest COGS position. |
| Time to market | MediumJan 1 target, but gated by DD, transition & integration risk. | SlowestFormulation, manufacturing, ops build — quarters, not weeks. | Fastest~90 days to 5 live SKUs (Nicholson plan). |
| Resourcing | HeaviestAcquisition, integration, follow-on capex, real operational distraction. | Heavy — internalLargest internal eng + ops build; opportunity cost on the roadmap. | Lightest~$45K at risk, small team, fully reversible. |
These don't force a single winner — they sequence. Partner wins time-to-market and reversibility, so it's how we enter. Buy wins control of the formulary, brand and customer book — so it's how we eventually own, once the attach data earns it. But note the pack-out reality: buying Persona doesn't capture manufacturing margin, so its COGS edge over a strong private-label partner is real yet narrower than "owned." Build loses on every axis that matters here.
The asset ledger — and how much of it is real.
What could make this a mistake.
- Low margin, high CAC — do we have a right to win? The category has said no twice: Care/of (Bayer bought 70% at a $225M valuation in 2020, switched the funding off in 2024) and Persona under Nestlé. Unit economics never closed.
- The inventory & equipment may be weak — and carry a big follow-on investment to modernize.
- Operational distraction — a full acquisition could delay more important projects (the roadmap on slide 06.5).
- The email list may be worthless — dormant profiles convert at ~0%.
Why this time can be different
Care/of failed because "personalization" was a quiz on a commodity, sold cold to strangers at high CAC. We change three of those variables:
- Captive audience — GLP-1 patients we already acquired, ~$0 incremental CAC
- Real personalization — driven by bloodwork, not a questionnaire
- Owned rails — telehealth, prescribers, fulfillment already built
That's the "right to win" Care/of never had. The risk isn't the category — it's overpaying and over-committing before we've proven the attach.
What problem are we actually solving?
If it's cash
The category is good, the timing is just expensive. Change the terms — earnout, seller financing, staged/minority-first close, delayed cash.
If it's a dead category
The unit economics can't be made to work for us. Walk away — cleanly, and keep the relationship warm.
If it's distraction / timing
Right asset, wrong moment. Push & lock in — which, in practice, looks a lot like the cash answer.
The evidence in this deck points to cash + timing — not a dead category. So the recommendation writes itself.
Enter now. Own later.
Let the data buy the company.
1 · Enter — this quarter
Launch 5 SKUs through a low-minimum partner (Vitalabs). ~$45K at risk, ~90 days, fully reversible. Measured on core-program retention.
2 · Lock in — reframe Persona
Convert the LOI from "buy it all now" to a staged / optioned structure (earnout, delayed close) that preserves the asset without the upfront cash or distraction.
3 · Decide — on evidence
Let the 90-day attach & retention data decide whether to accelerate the full acquisition and own the supply chain.
Supplements are the right category — for retention, diversification, enterprise value, and B2B leverage through HealthGrid. Persona is a genuine way to own the brand, formulary and customer book of that category — it's packaging + pack-out, not a manufacturing plant, so price it as such. We just don't have to bet the roadmap to find out. Enter cheap, prove the attach, and let that number set the price and pace of the buy.